Fragile X Syndrome — Deal Benchmarks & Valuation
Market Analysis
Fragile X Syndrome is one of the most actively transacted indications in rare disease licensing. Phase 2 deals for fragile x syndrome carry a median total deal value of $2.1B, with upfront payments ranging from $192M to $592M. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones.
Milestone structures for fragile x syndrome deals allocate $379M to development milestones, $431M to regulatory milestones, and $913M to commercial milestones. Royalty rates range from 7.6% to 15.1% at the base tier, with tiered escalation reaching 11.6%-19.1% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for fragile x syndrome licensing?
What royalty rates are standard for fragile x syndrome deals?
How are fragile x syndrome deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.